ENANTA PHARMACEUTICALS INC (ENTA) research
ENANTA PHARMACEUTICALS INC- Sector
- Biotechnology
- Last price
- $12.96
- As of
ENANTA PHARMACEUTICALS INC (ENTA): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-12.
As of . Source: SEC EDGAR filings for ENTA. Method and limitations.
Share the ENTA intelligence card
See the full ENTA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ENTA on one page. Preview it with sample data, then open it live with a free account.
Preview the ENTA dossierActive signals for ENTA
- highCONSENSUS_SELL
3 tracked funds reduced ENTA this 2026Q2, institutional consensus
- mediumEARNINGS_MISS
Q3-2026: Missed consensus by 28.8%, EPS $-0.67 vs $-0.5202 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +51% to ENTA (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 51% of ENTA (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 73% of ENTA (2026Q2)
FREE, NO ACCOUNT
Every signal on ENTA, as it fires
You are seeing 5 of 11 signals recorded on ENTA since 2026-05-29.
The five above landed across 3 days. The other 6 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ENTA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 29251M106 · 2026Q2 | $9.4M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 29251M106 · 2026Q2 | $8.1M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 29251M106 · 2026Q2 | $1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 29251M106 · 2026Q2 | $741K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 29251M106 · 2026Q2 | $504K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ENTA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
ENTA against its peers
ENTA's operating margin of -130.7% ranks in the 65th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | ENTA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 65.3M USD | 35.9M USD | 68 | 13 |
| Operating margin | -130.7% | -242.4% | 65 | 12 |
| Net margin | -125.4% | -247.7% | 65 | 12 |
| Return on equity | -126.5% | -69.4% | 25 | 13 |
Peers (18): IRD, ARCT, CCCC, FENC, OBIO, TTRX, GALT, ZURA, PROK, SRZN, RLMD, EDIT, SPRY, OCGN, KYTX, MYGN, ARTV, AGEN. Left out: RZLT (period gap), SCTX (no annual filing), BNTC (period gap), EIKN (no annual filing), PRTC (period gap), AGMB (no annual filing), VOGX (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ENTA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ENTA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ENTAand get the insider, 13F, options, and confluence read in one view.